ICH E6(R3) GCP and its 3 linked instruments

How to read this page

First column: ICH E6(R3) GCP. The others are every document linked to it.
Scroll sideways if there are more columns than fit.
It does not compare content. It does not say which is stricter. Read the official texts for that.

Details: Guide Definitions: every term and label explained

	ICH E6(R3) GCP	FDA BA/BE data integrity	EMA AI reflection paper	EMA notice: CS in trials
Authority	ICH	FDA	EMA	EMA
Legal weight	Guidance & Q&A	Guidance & Q&A	Guidance & Q&A	Guidance & Q&A
Status	Final	Draft	Final	Final
Last verified	Not yet	Not yet	Not yet	Not yet
Summary	Revised ICH guideline on good clinical practice. FDA says it adds flexible, risk-based approaches and embraces innovations in trial design, conduct and technology.	Draft FDA guidance for applicants and testing sites on achieving and maintaining data integrity in the clinical and bioanalytical parts of bioavailability and bioequivalence studies.	EMA's current thinking on AI and machine learning for human and veterinary medicines, covering principles that apply at any stage of a medicine's lifecycle, from drug discovery to after authorisation.	EMA notice to clinical trial sponsors on validating and qualifying computerised systems, such as electronic case report forms and patient reported outcome tools.
Lifecycle	8 Sep 2025 Published by FDA as final guidance	3 Apr 2024 Draft guidance issued	19 Jul 2023 Draft released for public consultation 31 Dec 2023 Public consultation closed 9 Sep 2024 Final version adopted by CHMP 30 Sep 2024 Final version published	7 Apr 2020 First published 29 Oct 2026 Revision 1: administrative update of references
Source	Official text Source: ICH.	Official text Source: FDA. Public domain.	Official text Source: EMA.	Official text Source: EMA.

These facts are placed side by side from each record. This page does not say which is stricter or whether requirements differ. Read the official texts.